Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
0.3831
-0.0292 (-7.08%)
At close: Aug 7, 2025, 4:00 PM
0.3799
-0.0032 (-0.84%)
Pre-market: Aug 8, 2025, 8:28 AM EDT
Clearside Biomedical Revenue
Clearside Biomedical had revenue of $2.33M in the quarter ending March 31, 2025, with 913.04% growth. This brings the company's revenue in the last twelve months to $3.76M, down -55.47% year-over-year. In the year 2024, Clearside Biomedical had annual revenue of $1.66M, down -79.77%.
Revenue (ttm)
$3.76M
Revenue Growth
-55.47%
P/S Ratio
7.69
Revenue / Employee
$117,625
Employees
32
Market Cap
30.07M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.66M | -6.56M | -79.77% |
Dec 31, 2023 | 8.23M | 6.90M | 519.89% |
Dec 31, 2022 | 1.33M | -28.25M | -95.51% |
Dec 31, 2021 | 29.58M | 21.68M | 274.65% |
Dec 31, 2020 | 7.89M | 5.72M | 263.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Eli Lilly and Company | 49.00B |
CLSD News
- 16 days ago - Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - GlobeNewsWire
- 22 days ago - Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - GlobeNewsWire
- 7 weeks ago - Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewsWire
- 2 months ago - Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewsWire
- 3 months ago - Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - GlobeNewsWire
- 3 months ago - Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 - GlobeNewsWire
- 3 months ago - Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference - GlobeNewsWire